Factive's potential value worths 244.3 billion won

As the Advisory Committee of the US FDA consisting of outside experts recommended the approval of LG Life Sciences' novel fluoroquinolone antibiotic Factive through hearings on March 4, the FDA will be likely to approve the new drug in the early April according to the opinions of the influential Advisory Committee.

Analyst Kim Jae-soon from Mirae Asset Securities said, "Since the FDA's reser...